Fate Therapeutics, Inc. Forecast, price target & analysts
Fate Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Fate Therapeutics, Inc. Classifications & Recommendation:
Fate Therapeutics, Inc. Price Target
| Target Price | $6.59 |
| Price | $0.68 |
| Potential |
869.25%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target Fate Therapeutics, Inc. 2026 .
The average Fate Therapeutics, Inc. target price is $6.59.
This is
869.25%
register free of charge
$12.00
1,664.71%
register free of charge
$2.50
267.65%
register free of charge
|
|
| A rating was issued by 14 analysts: 4 Analysts recommend Fate Therapeutics, Inc. to buy, 10 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Fate Therapeutics, Inc. stock has an average upside potential 2026 of
869.25%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 13.63 | 3.28 |
| 78.55% | 75.94% | |
| EBITDA Margin | -1,295.52% | -6,199.05% |
| 416.57% | 378.50% | |
| Net Margin | -1,370.84% | -5,375.79% |
| 366.10% | 292.15% |
14 Analysts have issued a sales forecast Fate Therapeutics, Inc. 2025 . The average Fate Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Fate Therapeutics, Inc. EBITDA forecast 2025. The average Fate Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
15 Fate Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Fate Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.64 | -1.55 |
| 0.00% | 5.49% | |
| P/E | negative | |
| EV/Sales | negative |
15 Analysts have issued a Fate Therapeutics, Inc. forecast for earnings per share. The average Fate Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Fate Therapeutics, Inc....
Current Fate Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Needham |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
| Stifel |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
| Wedbush |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Nov 19 2024 |
| Needham |
Locked
➜
Locked
|
Locked | Nov 13 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 22 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Needham:
Locked
➜
Locked
|
Mar 06 2025 |
|
Locked
Stifel:
Locked
➜
Locked
|
Mar 06 2025 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Mar 06 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Mar 06 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Nov 19 2024 |
|
Locked
Needham:
Locked
➜
Locked
|
Nov 13 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 22 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
